Clinical Trial Update: Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating allogeneic hematopoietic stem cell transplantation for chronic granulomatous disease using alemtuzumab, busulfan, and tota…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulomatous Disease

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• BUSULFAN (Busulfan)
• Emapalumab (emapalumab)
• Tocilizumab (tocilizumab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Chronic Granulomatous Disease | Phase 1, Phase 2 | Status: RECRUITING